Table 3.

Effect of fluvoxamine dose and baseline LSAS-J scores on the occurrence of adverse drug reactions (ADRs)

	N a	ADRs, n (%)	Logistic regression analysis
			OR	95 % CI	p value
Total dose of fluvoxamine, gb
≤2	328	207 (63.1)	0.631	0.594, 0.670	<0.0001
2–4	126	26 (20.6)
4–8	160	22 (13.8)
8–12	118	19 (16.1)
12–16	95	11 (11.6)
16–20	157	10 (6.4)
20–24	75	5 (6.7)
24–28	81	11 (13.6)
28–32	79	3 (3.8)
32–36	68	2 (2.9)
36–40	91	3 (3.3)
>40	408	4 (1.0)
Unknown	4	3 (75.0)
Maximum daily dose of fluvoxamine, mgb
≤25	65	18 (27.7)	0.714	0.663, 0.768	<0.0001
25–50	423	142 (33.6)
50–75	177	22 (12.4)
75–100	447	79 (17.7)
100–125	14	2 (14.3)
125–150	505	46 (9.1)
>150 mg	155	14 (9.0)
Final daily dose of fluvoxamine, mgb
≤25	118	22 (18.6)	0.775	0.721, 0.833	<0.0001
25–50	505	146 (28.9)
50–75	172	23 (13.4)
75–100	457	82 (17.9)
100–125	11	3 (27.3)
125–150	407	3 (8.6)
>150	116	12 (10.3)
Baseline LSAS-J total score
≤29	97	16 (16.5)	1.007	0.956, 1.060	0.7961
30–39	81	12 (14.8)
40–49	130	25 (19.2)
50–59	173	35 (20.2)
60–69	191	35 (18.3)
70–79	224	40 (17.9)
80–89	211	43 (20.4)
90–99	213	37 (17.4)
≥100	323	59 (18.3)
≤59	481	88 (18.3)	1.008	0.766, 1.327	0.9540
≥60	1,162	214 (18.4)

ADR adverse drug reaction, CI confidence interval, LSAS-J Liebowitz Social Anxiety Scale-Japanese version, N number of patients, OR odds ratio

^aPatients with no relevant information were excluded from analysis

^bTotal dose of fluvoxamine for patients with ADRs was calculated as total dose by the onset of the first ADR